(Q53247595)

English

Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study.

scientific article published in October 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

1 reference

based on heuristic

inferred from title

erectile dysfunction

1 reference

based on heuristic

inferred from title

author name string

Koichi Nagao

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

Yasusuke Kimoto

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

Ken Marumo

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

Akira Tsujimura

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

G Matthew Vail

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

Steven Watts

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

Nobuhisa Ishii

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

Sadao Kamidono

8

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

language of work or name

0 references

publication date

1 October 2006

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

68

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

845-851

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

The worldwide prevalence and epidemiology of erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Tadalafil pharmacokinetics in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

The efficacy and safety of tadalafil: an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

The randomization and stratification of patients to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

The efficacy of tadalafil in clinical populations

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.001

7 January 2021

Identifiers

10.1016/J.UROLOGY.2006.05.001

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17070365

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53247595&oldid=1504778744"